QY Research has recently released its new report, titled “Global Neurological Biomarkers Market Report, History and Forecast 2014-2025.” It evaluates the trends and opportunities, key market dynamics, historical data and key market segments for the predicted period of 2019-2025.
As per the report, the global neurological biomarkers market is expected to touch the valuation at US$8950 mn by the end of 2025 from US$4710 mn in the year 2018. The market is likely to register a CAGR of 9.6% throughout the anticipated period.
Global Neurological Biomarkers Market: Trends and Opportunities
The market will witness significant growth in the forthcoming years because of existing neurological disorders cases among patients across the world. Neurological biomarkers are indicators for measuring pathological and physiological processes to determine therapeutic intervention. Neuropathologists are extensively using these biomarkers for making an accurate diagnosis. Rising research and development activities due to increasing incidences of neurological disorders in a large population base are expected to boost the market.
Biomarkers are used for patients who are suffering from acute ischemic stroke, subarachnoid hemorrhage, traumatic brain injury, and intracerebral hemorrhage. The recovery from such diseases such as neurocritical diseases and crucial diseases is mainly dependent on the condition of the patient. Such type of diseases may get delayed for proper examining of the patients because of certain complexities. To measure these problems, there has been a need for biomarkers, which, in turn, is expected to drives the growth of the market.
Global Neurological Biomarkers Market: Regional Outlook
North America is anticipated to grab the largest market share of the neurological biomarkers due to the presence of a large number of key players and the numerous research and development activities are carried out in this region. Europe is also expected to hold the largest market share in the coming years.
Global Neurological Biomarkers Market: Segment Analysis
The global market for neurological biomarkers is segmented into applications and product type. The application segment is segmented into personalized medicine, diagnostics, drug discovery, and others. On the basis of product type, the market is further segmented into bioinformatics, proteomics, imaging, genomics, and others. Genomics segment is likely to consider the largest market segment as the demand for customizing medicines remains high amongst patients and medical professionals.
Global Neurological Biomarkers Market: Leading Players
Some of the top players operating in the market are Genewiz, Thermo Fisher Scientific, Proteome Sciences, Merck, Aepodia, Quest Diagnostics, Wuxi APP, Abbott, BGI, Roche, Athena Diagnostics, Illumina, Cisbio Bioassays, Bio-Rad Laboratories, Myriad RBM, and QIAGEN.
Global Neurological Biomarkers Market: Competitive Landscape
The companies are using various strategies such as the development of innovative products, collaborations, and mergers and acquisitions for expanding their business revenue in the competitive market. For instance, in May 2019, Thermo Fisher Scientific announced that the organization is acquiring one of the drug substance manufacturing site in Ireland, Cork for GlaxoSmithKline for approximately €90 mn in cash. The Cork site will expand its capacity to meet the need and requirements of the consumer for the development of the commercial producing of the complex APIs.
Full Report Overview@ https://www.qyresearch.com/index/detail/1076292/global-neurological-biomarkers-market